Beactica Wins Grant to Develop Combination Therapy for Glioblastoma

Tuesday, June 18, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

STOCKHOLM, June 18, 2019 /PRNewswire/ -- Beactica AB, the Swedish drug discovery company, today announced that it has been awarded a grant of 2.8 MSEK (~$300 000) from SweLife and Medtech4Health for its project focused on finding effective therapies for glioblastoma, an aggressive form of brain cancer. Treatment methods for glioblastoma have shown no significant improvement

for the last 15 years and Beactica serves to meet this unmet need through the development of allosteric modulators of an enzyme called LSD1. 

The compound developed by Beactica, BEA-17, recently showed indication of efficacy in an in vivo proof-of-principle study. The currently funded project is coordinated by Beactica and part of a collaboration with Uppsala University, the Akademiska Hospital in Uppsala and the SciLifeLab Drug Discovery and Development Platform. It aims to establish synergistic effects of BEA-17 in combination with currently approved anti-cancer agents. Beactica's allosteric LSD1 modulators have also shown efficacy in models of treatment-resistant glioblastoma. 

"We are delighted about the recognition that this important project continues to receive," said Per Källblad, CEO of Beactica. "It is clear that BEA-17 is a promising compound on its own, but a combination therapy may create the synergy needed to maximise the clinical outcome in glioblastoma."

Beactica's LSD1 programme focuses on the development of first-in-class small molecule allosteric modulators of LSD1 to treat glioblastoma and other cancers. Beactica's compounds have a fundamentally different mechanism of action from catalytic LSD1 inhibitors under development, and have been shown to exhibit in vivo efficacy in advanced oncology models.

The joint initiative from SweLife and Medtech4Health awards high-quality life science projects and Beactica's project is one of 16 innovative proposals sharing the amount of 41 MSEK, out of 122 applicants.

Beactica AB Contact:Per Källblad M.Sc. Ph.D.CEOper.kallblad@beactica.com Tel: +46-18-56-08-80

Notch Communications Contact:Kate Whelan Ph.D.kate.whelan@notchcommunications.se Tel: +46 (0)70-238-11-49 / +44 (0)161-457-7230

This information was brought to you by Cision http://news.cision.com

Cision View original content:http://www.prnewswire.com/news-releases/beactica-wins-grant-to-develop-combination-therapy-for-glioblastoma-300870101.html

SOURCE Beactica AB



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store